Serina Therapeutics Inc SER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.74
- Day Range
- $1.72–1.82
- 52-Week Range
- $1.27–7.84
- Bid/Ask
- $1.80 / $1.88
- Shares Outstanding
- 15.00M
- Market Cap
- $27.30M
- Volume/Avg
- 21,816 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
Valuation
|
Metric
|
SER
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.08 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SER
|
|---|---|
Quick Ratio | 3.87 |
Current Ratio | 4.18 |
Interest Coverage | −51.90 |
Quick Ratio
SER
Profitability
|
Metric
|
SER
|
|---|---|
Return on Assets (Normalized) | −180.55% |
Return on Equity (Normalized) | −3,637.52% |
Return on Invested Capital (Normalized) | −343.82% |
Return on Assets
SER
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dddbkxmm | Zvpjq | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mwdkhtzd | Rwtwrj | $63B | |||
| argenx SE ADR
ARGX
| Zqwhqwh | Jwvqy | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cwprvxmc | Btzvc | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Bfwxkdpbd | Wncmjs | $24B | |||
| BioNTech SE ADR
BNTX
| Rvqbffp | Wlg | $22B | |||
| Incyte Corp
INCY
| Xfxkshp | Zbf | $21B | |||
| Moderna Inc
MRNA
| Cnpxdsfq | Djtt | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rxqwqkny | Bvrbm | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Cqgfqnh | Rhc | $13B |
United States